Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street

Clear Street raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $680 from $533 and keeps a Buy rating on the shares post the Q1 report. The firm says the company’s Rezdiffra momentum continues. Management highlighted continued momentum into Q2, including the strongest month of patient adds since launch, the analyst tells investors in a research note.